ClinicalTrials.gg
CompletedNCT00711880Updated Apr 12, 2023Results posted

A Study of Sativex® for Relief of Peripheral Neuropathic Pain Associated With Allodynia.

A Phase 3 interventional study of Sativex® and Placebo in Pain and Peripheral Neuropathy, sponsored by Jazz Pharmaceuticals. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-12.

Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 17 studies testing nabiximols in Pain — none open to participants now, none under way, none of them phase 3. nabiximols · Pain.

Enrollment
11th of 17
125 · median 246
Started
2002
with 5 others
Phase 3
15 of 17
none open now
Registered
6th of 17
by date
Lead sponsor
14 of 17
Jazz Pharmaceuticals

Among the 17 studies testing nabiximols in Pain, this one is the 11th largest by enrollment, is one of 6 that started in 2002, is one of 15 in phase 3, and was the 6th registered.

Pain

10,075 studies on the registry are indexed under Pain; 1,649 are open to participants now.

Browse Pain studies →

Open to participants now

None of the 17 studies testing nabiximols in Pain is open now. The open studies under Pain, anywhere →

About nabiximols

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 433 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing nabiximols in Pain as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of Sativex® compared with placebo in relieving peripheral neuropathic pain associated with allodynia.

Read the detailed description

This was a six week, multicentre, double blind, randomised, placebo controlled parallel group study to evaluate the efficacy of Sativex®. Subjects with peripheral neuropathic pain characterised by allodynia, were screened to determine eligibility and entered a seven day baseline period. Subjects then returned to the centre for randomisation and dose introduction, and received either placebo or Sativex in a double blind manner for five weeks, with a follow up visit 7 to 10 days after the end of the treatment period. The primary efficacy measure was the difference in pain severity at the end of treatment, measured using a peripheral neuropathic pain 0 to 10 numerical rating scale.

03

Conditions studied

  • Pain
  • Peripheral Neuropathy

Keywords

  • Pain
  • Peripheral Neuropathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to give .
  • Male or female, aged 18 years or above.
  • Chronic peripheral neuropathic pain of at least six months duration.
  • Presence of mechanical allodynia within the territory of the affected nerve(s).
  • Evidence of sensory change in the affected nerve by simple clinical tests.
  • Peripheral neuropathic pain with a severity score of four or more on at least four completed NRS during the baseline week.
  • Stable dose of analgesic medication for at least two weeks leading to study entry.
  • Agreement, if female and of child bearing potential or if male with a partner of child bearing potential, to ensure that effective was used during the study and for three months thereafter.
  • Have not used cannabinoids (including cannabis, Marinol or Nabilone) for at least seven days before Visit 1 and were willing to abstain from any use of cannabinoids during the study.
  • Ability (in the investigator's opinion) and willingness to comply with all study requirements.
  • Agreement for the UK Home Office, their primary care physician, and their consultant if appropriate, to be notified of their participation in the study.

Exclusion criteria

Exclusion Criteria:

  • History of schizophrenia, other psychotic illness, severe personality disorder or other significant psychiatric disorder other than depression associated with their underlying condition.
  • Concomitant severe non-neuropathic pain or the presence of cancer related neuropathic pain or neuropathic pain resulting from diabetes mellitus.
  • Known history of alcohol or substance abuse.
  • Severe cardiovascular disorder, such as ischaemic heart disease, arrhythmias (other than well controlled atrial fibrillation), poorly controlled hypertension or severe heart failure.
  • History of epilepsy.
  • If female, were pregnant or lactating, or were planning a pregnancy to occur during the course of the study.
  • Significant renal or hepatic impairment.
  • Elective surgery or other procedures requiring general anaesthesia scheduled to occur during the study.
  • Terminal illness or were considered inappropriate for placebo medication.
  • Any other significant disease or disorder which, in the opinion of the investigator, may have either put the subject at risk because of participation in the study, or may influenced the result of the study, or the subject's ability to participate in the study.
  • Regular levodopa (Sinemet®, Sinement Plus®, Levodopa®, L-dopa®, Madopar®, Benserazide®) therapy within the seven days leading to study entry.
  • If male, were receiving and were unwilling to stop sildenafil (Viagra®) for the duration of the study.
  • Known or suspected to cannabinoids or any of the of the study medications.
  • Known or suspected adverse reaction to cannabinoids.
  • Intention to travel internationally during the study.
  • Intention to donate blood during the study.
  • Participation in another research study in the 12 weeks leading to study entry.
  • Previous randomisation into this study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    Sativex

    Drug: Sativex®

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugNabiximolsStudies of NabiximolsNabiximols pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours

    Also known as: GW-1000-02

  • DrugPlacebo

    containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.

    Also known as: GW-4001-01

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Mean Daily Peripheral Neuropathic Pain on a 0-10 Numerical Rating Scale Score During the Last Seven Days of Treatment (End of Treatment)

    The neuropathic pain Numerical Rating Scale was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate the number that best describes your pain or average pain in the last 24 hours" where 0 = no pain and 10 = worst possible pain. A negative value indicates an improvement in pain score from baseline.

    Time frame: Day 0 to Day 42

Secondary outcomes

  1. Change From Baseline in Mean Neuropathic Pain Scale Score at the End of Treatment

    The Neuropathic Pain Scale (NPS) score consisted of a series of assessments of different aspects of pain (intensity, sharpness, hot, dull, cold, sensitive, itchy, unpleasantness, and surface compared with deep), each scored using 11-point Numerical Rating Scales. The NPS score is 0-100 sum of 10 individual pain scores (0-10 NRS, 0= no pain to 10 = most pain imaginable). A negative change from baseline indicates an improvement in pain.

    Time frame: Day 0 to Day 42

  2. Change From Baseline in Mean Sleep Quality at the End of Treatment

    The sleep disruption NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate how your pain disrupted your sleep last night?" where 0 = did not disrupt sleep and 10 = completely disrupted (unable to sleep at all). A negative value indicates an improvement in sleep disruption score from baseline.

    Time frame: Day 7 - Day 42

  3. Change From Baseline in the Mean Pain Disability Index Score at the End of Treatment

    The Pain Disability Index consisted of seven self-administered questions relating to the effect of the subject's chronic pain on their personal life (family/home responsibilities, social activity, sexual behaviour, life-support activity, recreation, occupation and self-care). Each assessment was scored on an 11-point Numerical Rating Scale ranging from 0 (which equals 'no disability') to 10 (which equals 'total disability'). The total Pain Disability Index is the unweighted sum of the seven Numerical Rating Scale scores. The maximum (worst) total score was 70.

    Time frame: Day 0 - Day 42

  4. Change From Baseline in Mean Dynamic Allodynia Test Score at the End of Treatment

    Dynamic allodynia was assessed by stroking the skin over the affected area five times with a standardised brush, designed specifically for sensory testing at 5sec intervals, and recording the pain severity on a 0-10 point scale (0= no pain to 10 = most pain imaginable). All strokes were of the same length, minimum 2 cm. Each dynamic allodynia score was calculated as the average of the five strokes. A negative change from baseline indicates an improvement in score.

    Time frame: Day 7 and Day 42

  5. Change From Baseline in Mean Static Allodynia Test Score at the End of Treatment

    The static allodynia test involved applying pressure to a non-allodynic area (on the contralateral side to the identified allodynic area), and recording the pressure that caused pain to this area. Seventy five percent of the pressure that caused pain to the non-allodynic area (up to the subject's pain/pressure threshold) was then applied to the allodynic area, and an 11-point Numerical Rating Scale pain score recorded (between 0 (no pain)and 10 (most intense pain imaginable)). A negative value indicates an improvement in pain score from baseline.

    Time frame: Day 0 - Day 42

  6. Change From Baseline in Mean Total General Health Questionnaire Score at the End of Treatment

    The General Health Questionnaire-12 is designed to measure non-psychotic mental disorders. It consists of 12 questions, scored on a 0 to 3 Likert scale to measure and compare psychological morbidity levels, where 0 represents better psychological health. The total General Health Questionnaire-12 score is the unweighted sum of the 12 scores. Zero indicates the best possible psychological health, 36 indicates the worst possible psychological health.

    Time frame: Day 7 and Day 42

  7. Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Selective Reminding' at the End of Treatment

    The Selective Reminding Test measures verbal learning and delayed recall through a multiple-trial list-learning paradigm. Patients are presented aurally with a list of 12 words for trial 1 and are asked to recall as many as possible. For trials 2-6, there is a selective presentation of only those words not recalled on the previous trial. Trial 7 is similar to the other trials but is assessed after an 11-minute delay. The score for the selective reminding test is the unweighted average of seven individual study results (min=0 and max=84) Higher scores indicate a better cognitive performance.

    Time frame: Day 7 and Day 42

  8. Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for '10/36 Spatial Recall' at the End of Treatment

    The 10/36 Spatial Recall Test assesses visual spatial learning and delayed recall. Patients are asked to view a 6 x 6 checkerboard with ten checkers for 10 seconds. They are then asked to recreate the pattern viewed on a blank checkerboard. The number of correct responses from three immediate trials and one delayed trial (7 minute delay) are recorded. The Total number of correct responses is the unweighted sum from the four trials. The score for the 10/36 spatial recall test was the unweighted average of four individual study results (min=0 and max=40). A higher score indicates better cognitive performance.

    Time frame: Day 7 and Day 42

  9. Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Symbol Digit Modalities' at the End of Treatment

    The Symbol Digit Modalities Test measures complex attention and concentration in a task which also requires speed and accuracy in visual search and scanning. Patients are required to associate symbols with numbers and quickly generate the number when shown the symbol. The summary endpoint is the number of correct responses in 90 seconds. The symbol digit modalities test had a min of 0 and max score of 99. A higher score indicates better cognitive performance.

    Time frame: Day 7 and Day 42

  10. Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Paced Auditory Serial Addition Task' at the End of Treatment

    The Paced Auditory Serial Addition Task assesses sustained attention and concentration. A pre-recorded tape is used to present two series of 60 numbers, one every 3 seconds and one every 2 seconds. Patients are asked to add each number to the one immediately preceding it and give the result. The task summary score is the percentage of correct answers is calculated. The PASAT score range was 0% to 100%. Higher scores indicate a better cognitive

    Time frame: Day 7 and Day 42

  11. Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Word List Generation' at the End of Treatment

    Word list generation measures verbal associative fluency. Patients are given 60 seconds to give as many words beginning with a particular letter. The Total is the unweighted sum of all admissible words over three different trials. Higher scores indicate a better cognitive performance (min=0, max= not defined).

    Time frame: Day 7 and Day 42

  12. Subject Global Impression of Change in the Severity of Peripheral Neuropathic Pain at the End of Treatment

    Subjects were asked to give their impression of the overall change in their peripheral neuropathic pain since entry into the study using the following seven-point scale: 1 = 'Very Much Improved', 2 = 'Much Improved', 3 = 'Minimally Improved', 4 = 'No Change', 5 = 'Minimally Worse', 6 = 'Much Worse', 7 = 'Very Much Worse'. The number of subjects who reported an improvement is presented.

    Time frame: Day 42

  13. Change From Pre-dose in Mean Intoxication 100 mm Visual Analogue Scale Score at the End of Treatment

    Intoxication scores were measured using a 100 mm Visual Analogue Scale, where 0 equalled 'no intoxication' and 100 equalled 'extreme intoxication'. A negative value indicates an improvement in intoxication score from baseline.

    Time frame: Day 0 - Day 42

  14. Subject Global Impression of Change in the Severity of Allodynia in Their Chosen Allodynic Area at the End of Treatment

    Subjects were asked to give their impression of the overall change in their allodynia since entry into the study using the following seven-point scale: 1 = 'Very Much Improved', 2 = 'Much Improved', 3 = 'Minimally Improved', 4 = 'No Change', 5 = 'Minimally Worse', 6 = 'Much Worse', 7 = 'Very Much Worse'. A summary of the number and percentage of subjects

    Time frame: Day 0 - 42

  15. Incidence of Adverse Events as a Measure of Subject Safety

    The number of subjects who reported an adverse event during the course of the study is presented

    Time frame: Day 0 - Day 42

07

Results

Posted Sep 28, 2012

Participant flow

Participant flow — Overall Study
MilestoneSativexPlacebo
Started6362
Completed5055
Not completed137
Withdrew: Adverse event112
Withdrew: Patient non-compliance10
Withdrew: Lack of efficacy15

Outcome measures

PrimaryChange From Baseline in the Mean Daily Peripheral Neuropathic Pain on a 0-10 Numerical Rating Scale Score During the Last Seven Days of Treatment (End of Treatment)

The neuropathic pain Numerical Rating Scale was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate the number that best describes your pain or average pain in the last 24 hours" where 0 = no pain and 10 = worst possible pain. A negative value indicates an improvement in pain score from baseline.

Time frame:
Day 0 to Day 42
Reported as:
Mean · units on a scale
Change From Baseline in the Mean Daily Peripheral Neuropathic Pain on a 0-10 Numerical Rating Scale Score During the Last Seven Days of Treatment (End of Treatment)
units on a scaleSativexPlacebo
Change From Baseline in the Mean Daily Peripheral Neuropathic Pain on a 0-10 Numerical Rating Scale Score During the Last Seven Days of Treatment (End of Treatment)-1.57 ± 2.11-0.59 ± 1.38
Statistical analysis
  • Sativex vs Placebo · ANCOVA · p = 0.004 · Estimated mean treatment difference: -0.96 · 95% CI -1.59 to -0.32
SecondaryChange From Baseline in Mean Neuropathic Pain Scale Score at the End of Treatment

The Neuropathic Pain Scale (NPS) score consisted of a series of assessments of different aspects of pain (intensity, sharpness, hot, dull, cold, sensitive, itchy, unpleasantness, and surface compared with deep), each scored using 11-point Numerical Rating Scales. The NPS score is 0-100 sum of 10 individual pain scores (0-10 NRS, 0= no pain to 10 = most pain imaginable). A negative change from baseline indicates an improvement in pain.

Time frame:
Day 0 to Day 42
Reported as:
Mean · units on a scale
Change From Baseline in Mean Neuropathic Pain Scale Score at the End of Treatment
units on a scaleSativexPlacebo
Change From Baseline in Mean Neuropathic Pain Scale Score at the End of Treatment-9.7 ± 19.35-2.0 ± 12.14
Statistical analysis
  • Sativex vs Placebo · ANCOVA · p = 0.007 · Estimated mean treatment difference: -8.03 · 95% CI -13.83 to -2.23
SecondaryChange From Baseline in Mean Sleep Quality at the End of Treatment

The sleep disruption NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate how your pain disrupted your sleep last night?" where 0 = did not disrupt sleep and 10 = completely disrupted (unable to sleep at all). A negative value indicates an improvement in sleep disruption score from baseline.

Time frame:
Day 7 - Day 42
Reported as:
Mean · units on a scale
Change From Baseline in Mean Sleep Quality at the End of Treatment
units on a scaleSativexPlacebo
Change From Baseline in Mean Sleep Quality at the End of Treatment-0.82 ± 0.76-0.38 ± 0.68
Statistical analysis
  • Sativex vs Placebo · ANCOVA · p = 0.001 · Estimated mean treatment difference: -0.43 · 95% CI -0.67 to -0.19
SecondaryChange From Baseline in the Mean Pain Disability Index Score at the End of Treatment

The Pain Disability Index consisted of seven self-administered questions relating to the effect of the subject's chronic pain on their personal life (family/home responsibilities, social activity, sexual behaviour, life-support activity, recreation, occupation and self-care). Each assessment was scored on an 11-point Numerical Rating Scale ranging from 0 (which equals 'no disability') to 10 (which equals 'total disability'). The total Pain Disability Index is the unweighted sum of the seven Numerical Rating Scale scores. The maximum (worst) total score was 70.

Time frame:
Day 0 - Day 42
Reported as:
Mean · units on a scale
Change From Baseline in the Mean Pain Disability Index Score at the End of Treatment
units on a scaleSativexPlacebo
Change From Baseline in the Mean Pain Disability Index Score at the End of Treatment-5.6 ± 12.080.3 ± 8.71
Statistical analysis
  • Sativex vs Placebo · ANCOVA · p = 0.003 · Estimated mean treatment difference: -5.85 · 95% CI -9.62 to -2.09
SecondaryChange From Baseline in Mean Dynamic Allodynia Test Score at the End of Treatment

Dynamic allodynia was assessed by stroking the skin over the affected area five times with a standardised brush, designed specifically for sensory testing at 5sec intervals, and recording the pain severity on a 0-10 point scale (0= no pain to 10 = most pain imaginable). All strokes were of the same length, minimum 2 cm. Each dynamic allodynia score was calculated as the average of the five strokes. A negative change from baseline indicates an improvement in score.

Time frame:
Day 7 and Day 42
Reported as:
Mean · units on a scale
Change From Baseline in Mean Dynamic Allodynia Test Score at the End of Treatment
units on a scaleSativexPlacebo
Change From Baseline in Mean Dynamic Allodynia Test Score at the End of Treatment-1.15 ± 2.23-0.38 ± 1.72
Statistical analysis
  • Sativex vs Placebo · ANCOVA · p = 0.042 · Estimated mean treatment difference: -0.82 · 95% CI -1.60 to -0.03
SecondaryChange From Baseline in Mean Static Allodynia Test Score at the End of Treatment

The static allodynia test involved applying pressure to a non-allodynic area (on the contralateral side to the identified allodynic area), and recording the pressure that caused pain to this area. Seventy five percent of the pressure that caused pain to the non-allodynic area (up to the subject's pain/pressure threshold) was then applied to the allodynic area, and an 11-point Numerical Rating Scale pain score recorded (between 0 (no pain)and 10 (most intense pain imaginable)). A negative value indicates an improvement in pain score from baseline.

Time frame:
Day 0 - Day 42
Reported as:
Mean · units on a scale
Change From Baseline in Mean Static Allodynia Test Score at the End of Treatment
units on a scaleSativexPlacebo
Change From Baseline in Mean Static Allodynia Test Score at the End of Treatment18.22 ± 50.202.84 ± 44.43
Statistical analysis
  • Sativex vs Placebo · ANCOVA · p = 0.144 · Estimated mean treatment difference: 12.73 · 95% CI -4.40 to 29.85
SecondaryChange From Baseline in Mean Total General Health Questionnaire Score at the End of Treatment

The General Health Questionnaire-12 is designed to measure non-psychotic mental disorders. It consists of 12 questions, scored on a 0 to 3 Likert scale to measure and compare psychological morbidity levels, where 0 represents better psychological health. The total General Health Questionnaire-12 score is the unweighted sum of the 12 scores. Zero indicates the best possible psychological health, 36 indicates the worst possible psychological health.

Time frame:
Day 7 and Day 42
Reported as:
Mean · units on a scale
Change From Baseline in Mean Total General Health Questionnaire Score at the End of Treatment
units on a scaleSativexPlacebo
Change From Baseline in Mean Total General Health Questionnaire Score at the End of Treatment-3.0 ± 7.93-2.6 ± 5.72
Statistical analysis
  • Sativex vs Placebo · ANCOVA · p = 0.483 · Estimated mean treatment difference: -0.75 · 95% CI -2.84 to 1.35
SecondaryChange From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Selective Reminding' at the End of Treatment

The Selective Reminding Test measures verbal learning and delayed recall through a multiple-trial list-learning paradigm. Patients are presented aurally with a list of 12 words for trial 1 and are asked to recall as many as possible. For trials 2-6, there is a selective presentation of only those words not recalled on the previous trial. Trial 7 is similar to the other trials but is assessed after an 11-minute delay. The score for the selective reminding test is the unweighted average of seven individual study results (min=0 and max=84) Higher scores indicate a better cognitive performance.

Time frame:
Day 7 and Day 42
Reported as:
Mean · units on a scale
Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Selective Reminding' at the End of Treatment
units on a scaleSativexPlacebo
Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Selective Reminding' at the End of Treatment0.53 ± 1.100.48 ± 1.27
Statistical analysis
  • Sativex vs Placebo · ANCOVA · p = 0.924 · Estimated mean treatment difference: 0.02 · 95% CI -0.46 to 0.50
SecondaryChange From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for '10/36 Spatial Recall' at the End of Treatment

The 10/36 Spatial Recall Test assesses visual spatial learning and delayed recall. Patients are asked to view a 6 x 6 checkerboard with ten checkers for 10 seconds. They are then asked to recreate the pattern viewed on a blank checkerboard. The number of correct responses from three immediate trials and one delayed trial (7 minute delay) are recorded. The Total number of correct responses is the unweighted sum from the four trials. The score for the 10/36 spatial recall test was the unweighted average of four individual study results (min=0 and max=40). A higher score indicates better cognitive performance.

Time frame:
Day 7 and Day 42
Reported as:
Mean · units on a scale
Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for '10/36 Spatial Recall' at the End of Treatment
units on a scaleSativexPlacebo
Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for '10/36 Spatial Recall' at the End of Treatment0.79 ± 2.010.15 ± 2.12
Statistical analysis
  • Sativex vs Placebo · ANCOVA · p = 0.214 · Estimated mean treatment difference: 0.53 · 95% CI -0.31 to 1.38
SecondaryChange From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Symbol Digit Modalities' at the End of Treatment

The Symbol Digit Modalities Test measures complex attention and concentration in a task which also requires speed and accuracy in visual search and scanning. Patients are required to associate symbols with numbers and quickly generate the number when shown the symbol. The summary endpoint is the number of correct responses in 90 seconds. The symbol digit modalities test had a min of 0 and max score of 99. A higher score indicates better cognitive performance.

Time frame:
Day 7 and Day 42
Reported as:
Mean · units on a scale
Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Symbol Digit Modalities' at the End of Treatment
units on a scaleSativexPlacebo
Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Symbol Digit Modalities' at the End of Treatment1.6 ± 5.833.9 ± 7.38
Statistical analysis
  • Sativex vs Placebo · ANCOVA · p = 0.158 · Estimated mean treatment difference: -2.15 · 95% CI -5.15 to 0.85
SecondaryChange From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Paced Auditory Serial Addition Task' at the End of Treatment

The Paced Auditory Serial Addition Task assesses sustained attention and concentration. A pre-recorded tape is used to present two series of 60 numbers, one every 3 seconds and one every 2 seconds. Patients are asked to add each number to the one immediately preceding it and give the result. The task summary score is the percentage of correct answers is calculated. The PASAT score range was 0% to 100%. Higher scores indicate a better cognitive

Time frame:
Day 7 and Day 42
Reported as:
Mean · percentage of correct answers
Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Paced Auditory Serial Addition Task' at the End of Treatment
percentage of correct answersSativexPlacebo
Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Paced Auditory Serial Addition Task' at the End of Treatment8.0 ± 14.236.3 ± 9.25
Statistical analysis
  • Sativex vs Placebo · ANCOVA · p = 0.656 · Estimated mean treatment difference: 1.28 · 95% CI -4.47 to 7.04
SecondaryChange From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Word List Generation' at the End of Treatment

Word list generation measures verbal associative fluency. Patients are given 60 seconds to give as many words beginning with a particular letter. The Total is the unweighted sum of all admissible words over three different trials. Higher scores indicate a better cognitive performance (min=0, max= not defined).

Time frame:
Day 7 and Day 42
Reported as:
Mean · number of words
Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Word List Generation' at the End of Treatment
number of wordsSativexPlacebo
Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Word List Generation' at the End of Treatment3.5 ± 7.673.5 ± 8.47
Statistical analysis
  • Sativex vs Placebo · ANCOVA · p = 0.962 · Estimated mean treatment difference: -0.08 · 95% CI -3.56 to 3.39
SecondarySubject Global Impression of Change in the Severity of Peripheral Neuropathic Pain at the End of Treatment

Subjects were asked to give their impression of the overall change in their peripheral neuropathic pain since entry into the study using the following seven-point scale: 1 = 'Very Much Improved', 2 = 'Much Improved', 3 = 'Minimally Improved', 4 = 'No Change', 5 = 'Minimally Worse', 6 = 'Much Worse', 7 = 'Very Much Worse'. The number of subjects who reported an improvement is presented.

Time frame:
Day 42
Reported as:
Number · participants
Subject Global Impression of Change in the Severity of Peripheral Neuropathic Pain at the End of Treatment
participantsSativexPlacebo
Very Much Improved50
Much Improved116
Minimally Improved166
No Change2646
Minimally Worse02
Much Worse42
Very Much Worse00
Missing10
Statistical analysis
  • Sativex vs Placebo · Fisher Exact · p = <0.001 · Estimated mean treatment difference: 32.26 · 95% CI 16.40 to 48.12
SecondaryChange From Pre-dose in Mean Intoxication 100 mm Visual Analogue Scale Score at the End of Treatment

Intoxication scores were measured using a 100 mm Visual Analogue Scale, where 0 equalled 'no intoxication' and 100 equalled 'extreme intoxication'. A negative value indicates an improvement in intoxication score from baseline.

Time frame:
Day 0 - Day 42
Reported as:
Mean · units on a scale
Change From Pre-dose in Mean Intoxication 100 mm Visual Analogue Scale Score at the End of Treatment
units on a scaleSativexPlacebo
Change From Pre-dose in Mean Intoxication 100 mm Visual Analogue Scale Score at the End of Treatment3.2 ± 11.391.4 ± 10.74
SecondarySubject Global Impression of Change in the Severity of Allodynia in Their Chosen Allodynic Area at the End of Treatment

Subjects were asked to give their impression of the overall change in their allodynia since entry into the study using the following seven-point scale: 1 = 'Very Much Improved', 2 = 'Much Improved', 3 = 'Minimally Improved', 4 = 'No Change', 5 = 'Minimally Worse', 6 = 'Much Worse', 7 = 'Very Much Worse'. A summary of the number and percentage of subjects

Time frame:
Day 0 - 42
Reported as:
Number · participants
Subject Global Impression of Change in the Severity of Allodynia in Their Chosen Allodynic Area at the End of Treatment
participantsSativexPlacebo
Very Much Improved30
Much Improved123
Minimally Improved148
No Change3047
Minimally Worse12
Much Worse22
Very Much Worse00
Missing10
Statistical analysis
  • Sativex vs Placebo · Fisher Exact · p = 0.001 · Estimated mean treatment difference: 29.03 · 95% CI 13.39 to 44.67
SecondaryIncidence of Adverse Events as a Measure of Subject Safety

The number of subjects who reported an adverse event during the course of the study is presented

Time frame:
Day 0 - Day 42
Reported as:
Number · participants
Incidence of Adverse Events as a Measure of Subject Safety
participantsSativexPlacebo
Incidence of Adverse Events as a Measure of Subject Safety5748

Adverse events

Collected over All adverse events occurring from the time of consent to post study follow up i.e.8 weeks were collected. All deaths and serious adverse events occurring within 28 days of the final dose of study medication were also collected.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sativex—1/63 (1.6%)57/63 (90.5%)
Placebo—2/62 (3.2%)48/62 (77.4%)
Most frequent serious events
Most frequent serious events
EventSativexPlacebo
FallGeneral disorders0/631/62
Myelitis NOSNervous system disorders0/631/62
BronchopneumoniaInfections and infestations1/630/62
Transient ischaemic attackNervous system disorders1/630/62
HypoaesthesiaNervous system disorders0/630/62
Most frequent other events
Showing 10 of 32
Most frequent other events
EventSativexPlacebo
DizzinessNervous system disorders18/639/62
NauseaGastrointestinal disorders14/637/62
FatigueGeneral disorders13/635/62
Dry MouthGastrointestinal disorders11/633/62
Headache NOSNervous system disorders6/639/62
Vomiting Not Otherwise Specified (NOS)Gastrointestinal disorders8/633/62
Feeling drunkGeneral disorders6/630/62
ConstipationGastrointestinal disorders2/634/62
Application Site BurningGeneral disorders2/634/62
Diarrhoea NOSGastrointestinal disorders4/630/62

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)SativexPlaceboTotal
<=18 years000
Between 18 and 65 years5149100
>=65 years121325
Age, Continuous
Age, Continuous(years)SativexPlaceboTotal
Mean52.4 ± 15.854.3 ± 15.253.4 ± 15.4
Sex: Female, Male
Sex: Female, Male(Participants)SativexPlaceboTotal
Female353974
Male282351
Region of Enrollment
Region of Enrollment(participants)SativexPlaceboTotal
United Kingdom5150101
Belgium121224
08

Study locations

1 site
  • Clinical Trials Unit, The Walton Centre
    Fazakerley, Liverpool L9 7LJ, United Kingdom
09

References and documents

Publications

  • Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain. 2007 Dec 15;133(1-3):210-20. doi: 10.1016/j.pain.2007.08.028. Epub 2007 Nov 7. PubMed 17997224 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2002, a primary completion of Mar 2004 and a completion of Mar 2004. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2012, 8 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2008
First posted
Jul 9, 2008
Start
May 2002
Primary completionActual
Mar 2004
CompletionActual
Mar 2004
Results first posted
Sep 28, 2012
Last update
Apr 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00711880
Responsible party
Sponsor
First posted
Jul 9, 2008
Start date
May 2002
Primary completion
Mar 2004
Completion
Mar 2004
Results posted
Sep 28, 2012
Last update
Apr 12, 2023

Study contacts

Turo Nurmikko, MB BS PhD
principal investigator · Clinical Trials Unit, The Walton Centre

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nabiximols

Start the discussion